Drug Interactions between cladribine and efbemalenograstim alfa
This report displays the potential drug interactions for the following 2 drugs:
- cladribine
- efbemalenograstim alfa
Interactions between your drugs
cladribine efbemalenograstim alfa
Applies to: cladribine and efbemalenograstim alfa
Consumer information for this interaction is not currently available.
ADJUST DOSING INTERVAL: The safety and efficacy of recombinant human granulocyte colony-stimulating factors (rhG-CSF) administered simultaneously with cytotoxic agents, including cancer chemotherapy, have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.
MANAGEMENT: The prescribing information for pegfilgrastim, eflapegrastim, and efbemalenograstim alfa recommends that these products not be administered between 14 days before and 24 hours after antineoplastic agents.
References
- "Product Information. Neulasta (pegfilgrastim)." Amgen (2002):
- "Product Information. Rolvedon (eflapegrastim)." Spectrum Pharmaceuticals Inc 2 (2022):
- "Product Information. Ryzneuta (efbemalenograstim alfa)." Evive Biotech (2023):
Drug and food interactions
cladribine food
Applies to: cladribine
Cladribine oral products can bind to other medications. This may increase your risk of experiencing side effects. To avoid or minimize the interaction, cladribine should be taken at least 3 hours before or after other medications. Talk to your doctor if you have any questions or concerns, or if you have trouble separating the dosing times. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.